We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of coronavirus stock Inovio Pharmaceuticals (INO - Free Report) surged again on Tuesday. INO was up about 18% in late-morning trading and ended the trading day up 20.4% to $13.63.
There’s no specific news driving the stock, but investors are expecting new updates for its Covid-19 vaccine candidate INO-4800 soon. The biotech is awaiting FDA clearance to begin phase 2/3 trials in the US, which it anticipates will happen soon. CEO Joseph Kim also said that Inovio is “very confident” it will receive funding for the upcoming vaccine trials
INO has soared 300% year-to-date, and is up about 85% since the March market lows.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Why Inovio Pharmaceuticals Skyrocketed on Tuesday
Shares of coronavirus stock Inovio Pharmaceuticals (INO - Free Report) surged again on Tuesday. INO was up about 18% in late-morning trading and ended the trading day up 20.4% to $13.63.
There’s no specific news driving the stock, but investors are expecting new updates for its Covid-19 vaccine candidate INO-4800 soon. The biotech is awaiting FDA clearance to begin phase 2/3 trials in the US, which it anticipates will happen soon. CEO Joseph Kim also said that Inovio is “very confident” it will receive funding for the upcoming vaccine trials
INO has soared 300% year-to-date, and is up about 85% since the March market lows.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>